Drugs / SYHX1901
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04880512 | May 2021 → Aug 2022 | — | CSPC Ouyi Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06562894 | May 2025 → May 2027 expected | alopecia areata | CSPC Ouyi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06511739 | May 2024 → Aug 2025 | vitiligo | CSPC Ouyi Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05858047 | Apr 2023 → Feb 2024 | — | CSPC Ouyi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06943950 | Jun 2025 → Apr 2027 expected | psoriasis | CSPC Ouyi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-11-23 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - "SYHX1901 TABLETS" OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF SEVERE COVID-19 irasia.com ↗
The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the “SYHX1901 Tablets” developed by the Group has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials for the treatment of adult patients with severe Coronavirus Disease 2019 (COVID-19) in China. |
| 2021-03-16 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - DUAL INHIBITOR JAK-SyK "SYHX1901" OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-23 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - "SYHX1901 TABLETS" OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF SEVERE COVID-19 irasia.com ↗ |
| 2021-03-16 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - DUAL INHIBITOR JAK-SyK "SYHX1901" OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYHX1901 | “The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects” NCT04880512 ↗ |
| Route | Oral | “SYHX 1901, oral tablets, in fasted state” NCT04880512 ↗ |